PT  - JOURNAL ARTICLE
AU  - Ghaith Alhatemi
AU  - Mohamed Zghouzi
AU  - Yasar Sattar
AU  - Bachar Ahmad
AU  - Waqas Ullah
AU  - M. Chadi Alraies
TI  - Anticoagulation management of post-cardiac surgery new-onset atrial fibrillation
AID  - 10.3949/ccjm.89a.21003
DP  - 2022 Jun 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 329--335
VI  - 89
IP  - 6
4099  - http://www.ccjm.org/content/89/6/329.short
4100  - http://www.ccjm.org/content/89/6/329.full
SO  - Cleve Clin J Med2022 Jun 01; 89
AB  - New-onset post-cardiac surgery atrial fibrillation (PCSAF) is a frequent complication with estimated incidence of 17% to 64%, depending on type of surgery. It is associated with higher mortality, morbidity, and predisposition to stroke and systemic embolism postoperatively. Standard care involves rate or rhythm control, in addition to antithrombotic therapy in those with history of stroke, transient ischemic attack, or high risk of systemic thromboembolism. However, risk of bleeding is not negligible, and treating physicians should weigh the risks and benefits before committing to postoperative anticoagulation therapy. More investigations are warranted to explore antithrombotic therapy benefit, particularly postoperative anticoagulation, considering the potentially self-limited nature of the arrhythmia and high risk of postoperative bleeding.